Last reviewed · How we verify
OnabotulinumtoxinA (ONA)
OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction, paralyzing muscles and reducing dynamic wrinkles and muscle contractions.
OnabotulinumtoxinA blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Facial wrinkles and dynamic expression lines (cosmetic), Cervical dystonia, Chronic migraine.
At a glance
| Generic name | OnabotulinumtoxinA (ONA) |
|---|---|
| Also known as | Botox® |
| Sponsor | Hexsel Dermatology Clinic |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Dermatology, Neurology |
| Phase | FDA-approved |
Mechanism of action
OnabotulinumtoxinA is a botulinum toxin serotype A that cleaves SNARE proteins required for acetylcholine vesicle release. By preventing neurotransmitter release at the neuromuscular junction, it causes temporary paralysis of targeted muscles. This effect is used cosmetically to reduce facial wrinkles caused by muscle contraction and therapeutically to treat conditions involving muscle hyperactivity.
Approved indications
- Facial wrinkles and dynamic expression lines (cosmetic)
- Cervical dystonia
- Chronic migraine
- Blepharospasm
- Strabismus
- Hyperhidrosis
- Spasticity
Common side effects
- Headache
- Injection site pain or bruising
- Facial weakness or drooping
- Eyelid ptosis
- Brow ptosis
- Flu-like symptoms
- Neck pain
Key clinical trials
- Upper Limb Nerve Cryoneurolysis is Non Inferior to the Usual Care and Has Therapeutic Add Value in Dealing With Shoulder Pain and Functional Problems Caused by Spasticity and Motor Impairment (NA)
- The Effects of Waning of Botulinum Toxin in the Treatment of Cervical Dystonia (PHASE4)
- Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars (PHASE2, PHASE3)
- Fields Of Effects Of Two Commercial Preparations Of Botulinum Toxin Type A At Equal Labeled Unit Doses (PHASE4)
- Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OnabotulinumtoxinA (ONA) CI brief — competitive landscape report
- OnabotulinumtoxinA (ONA) updates RSS · CI watch RSS
- Hexsel Dermatology Clinic portfolio CI